Amplifiers

Biocept Provides Update on COVID-19 Testing with More than 350,000 Samples Received to Date

Wednesday, April 14, 2021 - 1:05pm

(Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that since the Company began offering SARS-CoV-2 testing services in June 2020, it has now received more than 350,000 samples for testing.

Key Points: 
  • (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that since the Company began offering SARS-CoV-2 testing services in June 2020, it has now received more than 350,000 samples for testing.
  • Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
  • The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release.
  • We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.

Eurofins Covid Testing Services Ltd (ECTS) Supports Reopening UK Travel by Making PCR Testing Affordable for All

Tuesday, April 13, 2021 - 4:45pm

b'Eurofins Covid Testing Services Ltd (ECTS) recognises the importance of testing in the fight against COVID-19.

Key Points: 
  • b'Eurofins Covid Testing Services Ltd (ECTS) recognises the importance of testing in the fight against COVID-19.
  • Only the PCR test can provide the accuracy, reliability and variant tracking required to ensure the continued safety of everyone in the UK and whilst travelling.\nECTS wants to support the airline, travel and tourism industries and facilitate travel for all by removing the barrier of expensive testing.
  • ECTS has therefore recently made significant investments in technology and automation to be able to drastically reduce the price of test-at-home PCR kits to just \xc2\xa344.90, providing the UK\xe2\x80\x99s lowest cost option for both Test-To-Depart and Test-To-Release.
  • With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins\xe2\x80\x99 companies offer a portfolio of over 200,000 analytical methods.\nEurofins Shares are listed on Euronext Paris Stock Exchange.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210413005843/en/\n'

GT Molecular launches highly sensitive PCR-based tests for UK, South African, and Brazilian/Japanese Variants of Concern

Wednesday, April 14, 2021 - 4:09pm

NationwideFee-for-servicetesting of wastewater samples for UK, South African, and Brazilian/Japanese Variants of SARS-CoV-2\n2.

Key Points: 
  • NationwideFee-for-servicetesting of wastewater samples for UK, South African, and Brazilian/Japanese Variants of SARS-CoV-2\n2.
  • "As mutations and variants gained traction, GT Molecular created new tools producing highly accurate, well-reported and timely variant data to our City, which has been shared throughout decision-makers in Florida.
  • GT Molecular\'s data has been validated by our state\'s lab as accurate and reliable.
  • says Dr. Lauren Stadler, Assistant Professor at Rice University.\nGT Molecular is a leader in providing highly customizable, ultrasensitive digital PCR and qPCR tests.

FDA Authorizes New High-Throughput, Automated System for Leading COVID-19 Test

Monday, April 12, 2021 - 1:00pm

"For population-wide testing programs, lab-based PCR is the best fitting technology, providing confidence in results, capacity to process thousands of samples a day, and consistent, reliable turnaround times.

Key Points: 
  • "For population-wide testing programs, lab-based PCR is the best fitting technology, providing confidence in results, capacity to process thousands of samples a day, and consistent, reliable turnaround times.
  • The Amplitude Solution can help support a systematic testing strategy by enabling labs to quickly scale their testing and begin processing high-volume samples, even with limited personnel.
  • "\nThe Amplitude Solution is a molecular diagnostic testing system that helps clinical labs expand testing capacity by combining Thermo Fisher\'s extraction and real-time PCR instruments with liquid handling products from Tecan Group.
  • 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.\nThermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion.

Oligonucleotide Synthesis Market worth $14.1 billion by 2026 - Exclusive Report by MarketsandMarkets™

Friday, April 9, 2021 - 3:30pm

Based on end users, the oligonucleotide synthesis market is categorized into hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, contract manufacturing organizations (CMOs) & contract research organizations (CROs), and academic & government institutes.

Key Points: 
  • Based on end users, the oligonucleotide synthesis market is categorized into hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, contract manufacturing organizations (CMOs) & contract research organizations (CROs), and academic & government institutes.
  • The PCR sub segment accounted for the largest share of the research application segment in the oligonucleotide synthesis market in 2020.
  • These PCR applications utilize sequence-specific primers, thus boosting the market for oligos (which are used as probes and primers) in the PCR market.
  • The Asia Pacific region is the fastest growing region of the oligonucleotide synthesis market in 2020.

Oligonucleotide Synthesis Market worth $14.1 billion by 2026 - Exclusive Report by MarketsandMarkets™

Friday, April 9, 2021 - 3:30pm

Based on end users, the oligonucleotide synthesis market is categorized into hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, contract manufacturing organizations (CMOs) & contract research organizations (CROs), and academic & government institutes.

Key Points: 
  • Based on end users, the oligonucleotide synthesis market is categorized into hospitals, pharmaceutical & biotechnology companies, diagnostic laboratories, contract manufacturing organizations (CMOs) & contract research organizations (CROs), and academic & government institutes.
  • The PCR sub segment accounted for the largest share of the research application segment in the oligonucleotide synthesis market in 2020.
  • These PCR applications utilize sequence-specific primers, thus boosting the market for oligos (which are used as probes and primers) in the PCR market.
  • The Asia Pacific region is the fastest growing region of the oligonucleotide synthesis market in 2020.

Applied DNA CEO Discusses Relevance of DNA-based Cotton Traceability as Enabler of Ethical and Responsible Textile Manufacturing on BBC Business Daily

Thursday, April 8, 2021 - 3:00pm

To date, CertainT has ensured the authenticity of approximately 300 million pounds of North American Pima and Upland cotton and has been deployed to secure Egyptian and Australian cotton.

Key Points: 
  • To date, CertainT has ensured the authenticity of approximately 300 million pounds of North American Pima and Upland cotton and has been deployed to secure Egyptian and Australian cotton.
  • CertainT begins by authenticating the fiber content in cotton to confirm its origin.
  • The platform then employs a unique molecular identifier produced by the Companys LinearDNA platform to mark cotton fibers in bulk.
  • Applied DNA is commercializing LinearDNA, its proprietary, large-scale polymerase chain reaction (PCR)-based manufacturing platform that allows for the large-scale production of specific DNA sequences.

Hologic to Acquire Mobidiag, Innovator in Near-Patient, Acute Care Diagnostic Testing, for Approximately $795 Million

Thursday, April 8, 2021 - 1:00pm

This includes a cash payment of approximately $714 million (600 million) for Mobidiags equity, and net debt of approximately $81 million.

Key Points: 
  • This includes a cash payment of approximately $714 million (600 million) for Mobidiags equity, and net debt of approximately $81 million.
  • Mobidiag develops and markets PCR (polymerase chain reaction)-based tests for acute care conditions such as gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare associated infections.
  • The Amplidiag and Novodiag platforms are automated instruments that deliver rapid turnaround times ranging from 50 minutes to two hours.
  • Mobidiag generated approximately $42 million (35 million) of revenue in calendar 2020.

Collection Sites Makes Affordable FDA EUA Approved COVID-19 At-Home Testing Available Nationwide

Thursday, April 8, 2021 - 12:30pm

The at-home test kits are available for purchase without a prescription by individuals through nationwide retail partners and by schools and businesses directly through the Collection Sites website.

Key Points: 
  • The at-home test kits are available for purchase without a prescription by individuals through nationwide retail partners and by schools and businesses directly through the Collection Sites website.
  • Collection Sites test kits are developed by a leading infectious disease laboratory and are based on the FDA EUA authorized SARS-CoV-2 RT-PCR assay.
  • Collection Sites expert lab processing and testing fee of $89.99 can be covered by health insurance or credit card.
  • The company provides pop-up COVID-19 lab testing services, business-focused testing services, and at-home testing services, powered by CLIA-licensed laboratories.

CareDx Announces New HLA Typing Service Offering for Research Purposes

Thursday, April 8, 2021 - 12:00pm

The CareDx HLA typing service powered by AlloSeq Tx17 enables best-in-class research by using innovative hybrid-capture technology with the highest level of resolution, no long-range PCR inefficiencies, and a fast turnaround time.

Key Points: 
  • The CareDx HLA typing service powered by AlloSeq Tx17 enables best-in-class research by using innovative hybrid-capture technology with the highest level of resolution, no long-range PCR inefficiencies, and a fast turnaround time.
  • CareDxs HLA typing service in Stockholm has been engaged by one of the top 10 global pharmaceutical companies in the world, providing initial testing results in the first quarter of 2021.
  • This is an exciting time for CareDx we are not only expanding our capabilities but also investing in our global team to provide a first ever CareDx testing service outside the United States, said Alexander Johnson, SVP, Products, Cell Therapy and Business Development, CareDx.
  • This expansion allows us to partner with those at the forefront of drug development research and support improved care for even more patients around the world.